A Pilot Study of RISE for Nurse Managers Retreat
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAdventHealth
About this trial
The purpose of this study is to determine the feasibility and acceptability of the RISE for Nurse Managers retreat and its impact on occupational and psychological well-being indicators
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
an employed AdventHealth Nurse Manager
a "moderate" or "high" score in burnout equal to ≥17 in the Emotional Exhaustion Domain and/or ≥7 in the Depersonalization Domain on the MBI
Disqualifiers
a direct care RN, Nurse Director, Educator, and Executive
a "low" score in burnout equal to <17 in the Emotional Exhaustion domain and/or <7 in the Depersonalization domain on the MBI
Trial design
Design model
Single group
Treatments tested in this trial
Intervention Group
BehavioralPsychoeducational group program designed to impact occupational and psychological indicators including resilience, insight, self-compassion, empowerment, burnout and secondary trauma
Treatment groups
16 Participants
are divided into 1 treatment groupGroup A: Participant groupExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Maslach Burnout Inventory - Human Services Survey
22-item questionnaire with the following response categories: 0=never, 1=a few times a year or less, 2=once a month or less, 3=a few times a month, 4=once a week, 5=a few times a week, 6=every day. MBI includes 3 dimensions of Burnout: Emotional Exhaustion, Depersonalization, and Personal Accomplishment. There are 9 items included in Emotional Exhaustion and scores can range from 0-54. There are 5 items included in Depersonalization and scores can range from 0-30. There are 8 items included in Personal Accomplishment and scores can range from 0-48. Higher scores on Emotional Exhaustion and Depersonalization and lower scores on Personal Accomplishment are indicative of Burnout
Time frame
Baseline, 1-month follow-up, 3-month follow-up, 6-month follow-upSecondary outcomes
1
Professional Quality of Life Scale
30-item questionnaire with the following response categories: 1=never, 2=rarely, 3=sometimes, 4=often, 5=very often. PROQOL includes 3 dimensions: Compassion Satisfaction, Burnout, and Secondary Traumatic Stress. Each subscale includes 10 items and scores can range from 10-50. For Burnout and Secondary Traumatic Stress, lower scores are better. Sums of 10-22 = low level, 23-41 = average level, and 42-50=high level of Burnout and Secondary Traumatic Stress. For Compassion Satisfaction, higher scores are better. Sum of 10-22=low level, 23-41=average level, and 42-50=high level of Compassion Satisfaction.
Time frame
Baseline, 1- and 3-and 6-month follow-up2
Brief Resilience Scale
6-item questionnaire with the following response categories: 1=strongly agree, 2=disagree, 3=neutral, 4=agree, 5=strongly agree. Sum of items can range from 6-30, which is then divided by 6 to get an average score. Higher score is better, with 1-2.99 = low resilience, 3-4.3 = normal resilience, and 4.31-5.0 = high resilience.
Time frame
Baseline, 1- and 3-and 6-month follow-up3
Self-Reflection and Insight Scale
20-item questionnaire with the following response categories: 1=strongly disagree, 2, 3, 4, 5, 6=strongly agree. Six items are included in Self-Reflection and scores can range from 6-42, with higher scores indicating a greater self-reflection. Six items are included in Insight, and scores can also range from 6-42 with higher scores indicating more Insight.
Time frame
Baseline, 1- and 3-and 6-month follow-up4
Self-Compassion Scale Short Form
12-item questionnaire with the following response categories: 1=almost never, 2, 3, 4, 5=almost always. Scores are added and then averaged. While the average score is to be used comparatively, score 1.0-2.49 is considered low, 2.5-3.5 is considered moderate, and 3.51-5.0 is considered high.
Time frame
Baseline, 1- and 3-and 6-month follow-upSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov